FDA clears Abbott's FreeStyle Libre 2 and 3 sensors for integration with AID systems
ozdigital
- Abbott (NYSE:ABT) announces that the FDA has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.
- Abbott modified the sensors to enable integration with AID systems.
- AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.
- Abbott is partnering with Insulet and Tandem for future integrations in multiple countries.
- The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors will be available in the U.S. later this year.